JP2015535832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535832A5 JP2015535832A5 JP2015533473A JP2015533473A JP2015535832A5 JP 2015535832 A5 JP2015535832 A5 JP 2015535832A5 JP 2015533473 A JP2015533473 A JP 2015533473A JP 2015533473 A JP2015533473 A JP 2015533473A JP 2015535832 A5 JP2015535832 A5 JP 2015535832A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- hal
- group
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- RVEOIAWOGIHTAH-FQEVSTJZSA-N CC(C)(CO)[C@H](C(NCCC(C(NCc(cc1)ccc1S(c1ccccc1)(=O)=O)=O)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCC(C(NCc(cc1)ccc1S(c1ccccc1)(=O)=O)=O)=O)=O)O RVEOIAWOGIHTAH-FQEVSTJZSA-N 0.000 description 1
- YONDKVCQXJTTAY-KRWDZBQOSA-N CC(C)(CO)[C@H](C(NCCN(CCCc1ccccc1)C(CF)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCN(CCCc1ccccc1)C(CF)=O)=O)O YONDKVCQXJTTAY-KRWDZBQOSA-N 0.000 description 1
- IAFNRNULFRXRMN-QFIPXVFZSA-N CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1-c1ccccc1)C(CCl)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1-c1ccccc1)C(CCl)=O)=O)O IAFNRNULFRXRMN-QFIPXVFZSA-N 0.000 description 1
- VHUCFYWMGFEVOC-INIZCTEOSA-N CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1Br)C(CCl)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1Br)C(CCl)=O)=O)O VHUCFYWMGFEVOC-INIZCTEOSA-N 0.000 description 1
- YHHJEFYQKSJXMQ-INIZCTEOSA-N CCNC(Nc1ccc(CNC(C(CCNC([C@@H](C(C)(C)CO)O)=O)=O)=O)cc1)=O Chemical compound CCNC(Nc1ccc(CNC(C(CCNC([C@@H](C(C)(C)CO)O)=O)=O)=O)cc1)=O YHHJEFYQKSJXMQ-INIZCTEOSA-N 0.000 description 1
- -1 ammonium ions Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185835.1 | 2012-09-25 | ||
| EP12185835 | 2012-09-25 | ||
| PCT/EP2013/002716 WO2014048547A1 (en) | 2012-09-25 | 2013-09-10 | Alpha hydroxy amides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015535832A JP2015535832A (ja) | 2015-12-17 |
| JP2015535832A5 true JP2015535832A5 (enExample) | 2016-12-22 |
Family
ID=46968027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533473A Ceased JP2015535832A (ja) | 2012-09-25 | 2013-09-10 | アルファヒドロキシアミド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9585891B2 (enExample) |
| EP (1) | EP2900633A1 (enExample) |
| JP (1) | JP2015535832A (enExample) |
| CN (1) | CN104703965A (enExample) |
| AU (1) | AU2013324696B2 (enExample) |
| CA (1) | CA2885778A1 (enExample) |
| IL (1) | IL237841A0 (enExample) |
| WO (1) | WO2014048547A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US8993555B2 (en) | 2012-12-21 | 2015-03-31 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| WO2015200680A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US10653693B2 (en) | 2014-08-04 | 2020-05-19 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2016072854A2 (en) | 2014-11-06 | 2016-05-12 | Radboud Universitair Medisch Centrum | Pantothenamide analogues |
| US10308615B2 (en) | 2015-05-29 | 2019-06-04 | Pfizer Inc. | Heterocyclic compounds as inhibitors of Vanin-1 enzyme |
| EP3386495A1 (en) * | 2015-12-08 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic sclerosis |
| MX2019000536A (es) | 2016-07-14 | 2019-04-01 | Pfizer | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. |
| DK3844161T3 (da) | 2018-08-28 | 2022-12-12 | Boehringer Ingelheim Int | Heteroaromatiske forbindelser som vanininhibitorer. |
| WO2020114947A1 (en) | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| SG11202104437XA (en) * | 2018-12-03 | 2021-05-28 | Boehringer Ingelheim Int | Heteroaromatic compounds as vanin inhibitors |
| JP7080405B2 (ja) | 2018-12-03 | 2022-06-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害剤としての複素芳香族化合物 |
| CN111592472B (zh) | 2019-04-28 | 2022-10-21 | 纳莹(上海)生物科技有限公司 | 一种荧光染料及其制备方法和用途 |
| US20250009694A1 (en) * | 2021-11-02 | 2025-01-09 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for repairing intestinal mucosal |
| JP7506415B2 (ja) * | 2021-12-17 | 2024-06-26 | 学校法人大阪医科薬科大学 | Ｖａｎｉｎ－１阻害剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2692895A (en) | 1950-08-23 | 1954-10-26 | Opfermann Adolf Christia Josef | Production of pantothenaldehyde and acetals thereof |
| JPS60248193A (ja) * | 1984-05-23 | 1985-12-07 | Dai Ichi Seiyaku Co Ltd | パンテテインの製造法 |
| US20040247524A1 (en) | 2003-06-05 | 2004-12-09 | Philippe Naquet | Method of treatment of an inflammatory disorder with a Vanin-1 antagonist |
| US7727738B2 (en) | 2005-07-11 | 2010-06-01 | The Regents Of The University Of California | Methods for generating analogs of coenzyme A |
| WO2011152720A1 (en) * | 2010-05-31 | 2011-12-08 | Umc St. Radboud | Pantothenic acid derivatives and their use in the treatment of microbial infections |
| US20130345270A1 (en) * | 2010-11-12 | 2013-12-26 | Waake Forest University Health Sciences | Methods of treating cancer and other disorders |
-
2013
- 2013-09-10 CA CA2885778A patent/CA2885778A1/en not_active Abandoned
- 2013-09-10 EP EP13759673.0A patent/EP2900633A1/en not_active Withdrawn
- 2013-09-10 AU AU2013324696A patent/AU2013324696B2/en not_active Ceased
- 2013-09-10 WO PCT/EP2013/002716 patent/WO2014048547A1/en not_active Ceased
- 2013-09-10 JP JP2015533473A patent/JP2015535832A/ja not_active Ceased
- 2013-09-10 CN CN201380049287.0A patent/CN104703965A/zh active Pending
- 2013-09-10 US US14/430,953 patent/US9585891B2/en not_active Expired - Fee Related
-
2015
- 2015-03-19 IL IL237841A patent/IL237841A0/en unknown